CA2395866C - Ophthalmic anti-allergy compositions suitable for use with contact lenses - Google Patents
Ophthalmic anti-allergy compositions suitable for use with contact lenses Download PDFInfo
- Publication number
- CA2395866C CA2395866C CA002395866A CA2395866A CA2395866C CA 2395866 C CA2395866 C CA 2395866C CA 002395866 A CA002395866 A CA 002395866A CA 2395866 A CA2395866 A CA 2395866A CA 2395866 C CA2395866 C CA 2395866C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- allergy
- olopatadine
- emedastine
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 19
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims abstract description 26
- 229960004114 olopatadine Drugs 0.000 claims abstract description 23
- 239000003755 preservative agent Substances 0.000 claims abstract description 16
- 230000002335 preservative effect Effects 0.000 claims abstract description 15
- 229960000325 emedastine Drugs 0.000 claims description 22
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims description 22
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical group Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 229960004677 emedastine difumarate Drugs 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 229960003139 olopatadine hydrochloride Drugs 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- FWLKKPKZQYVAFR-SPIKMXEPSA-N emedastine difumarate Chemical group OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-SPIKMXEPSA-N 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 7
- 239000004327 boric acid Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 6
- 150000003868 ammonium compounds Chemical class 0.000 description 5
- -1 buffering systems Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 229940073602 emadine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940097078 patanol Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17780400P | 2000-01-25 | 2000-01-25 | |
| US60/177,804 | 2000-01-25 | ||
| PCT/US2001/002418 WO2001054687A1 (en) | 2000-01-25 | 2001-01-24 | Ophthalmic anti-allergy compositions suitable for use with contact lenses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2395866A1 CA2395866A1 (en) | 2001-08-02 |
| CA2395866C true CA2395866C (en) | 2009-10-13 |
Family
ID=22650044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002395866A Expired - Fee Related CA2395866C (en) | 2000-01-25 | 2001-01-24 | Ophthalmic anti-allergy compositions suitable for use with contact lenses |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6375973B2 (enExample) |
| EP (1) | EP1250133B1 (enExample) |
| JP (2) | JP2003520813A (enExample) |
| AT (1) | ATE291913T1 (enExample) |
| AU (1) | AU776789B2 (enExample) |
| CA (1) | CA2395866C (enExample) |
| DE (1) | DE60109742T2 (enExample) |
| ES (1) | ES2236180T3 (enExample) |
| PT (1) | PT1250133E (enExample) |
| WO (1) | WO2001054687A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
| US7977376B2 (en) | 2001-06-27 | 2011-07-12 | Novartis Ag | Olopatadine formulations for topical nasal administration |
| US8388995B1 (en) | 2006-02-03 | 2013-03-05 | Auburn University | Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform |
| US8349352B2 (en) * | 2005-02-04 | 2013-01-08 | Auburn University | Therapeutic contact lenses with anti-fungal delivery |
| WO2006084275A2 (en) * | 2005-02-04 | 2006-08-10 | Auburn University | Contact drug delivery system |
| US9238003B2 (en) | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
| US7947010B2 (en) | 2005-07-08 | 2011-05-24 | Depuy Products, Inc. | Composition and system for wound decontamination |
| US7247623B2 (en) * | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
| US20080138408A1 (en) * | 2006-11-13 | 2008-06-12 | Siddharth Venkatesh | Drug delivery system and method |
| HUE026162T2 (en) * | 2007-02-07 | 2016-05-30 | Novartis Ag | Olopatadine preparation for topical nasal administration |
| CN103140215A (zh) * | 2010-07-21 | 2013-06-05 | 爱尔康研究有限公司 | 具有提高的溶解度特征的药物组合物 |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| TW201336527A (zh) * | 2012-02-10 | 2013-09-16 | Alcon Res Ltd | 具增強的穩定性之水性藥學組成物 |
| WO2014150899A1 (en) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
| WO2015065576A1 (en) * | 2013-10-31 | 2015-05-07 | Nephron Pharmaceuticals Corporation | Formulation of olopatadine |
| EP3037094A1 (en) * | 2014-12-23 | 2016-06-29 | Poifa Warszawa SA | Ophthalmic pharmaceutical composition |
| CN107875119B (zh) * | 2017-11-22 | 2021-03-12 | 山东绅联药业有限公司 | 一种富马酸依美斯汀水性药物组合物及其制备方法 |
| WO2025137749A1 (pt) * | 2023-12-27 | 2025-07-03 | Eurofarma Laboratórios S.A. | Processo de solubilização de olopatadina e seu uso |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3931319A (en) | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4027020A (en) | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| JPS5879983A (ja) | 1981-11-06 | 1983-05-13 | Kanebo Ltd | 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物 |
| US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| US4923892A (en) | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
| JPH08770B2 (ja) * | 1985-12-25 | 1996-01-10 | 千寿製薬株式会社 | 眼科用組成物 |
| JPS6310784A (ja) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
| US5037647A (en) * | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5192780A (en) | 1989-12-18 | 1993-03-09 | Alcon Laboratories, Inc. | Methods using antiallergics and antihistamines |
| AU636685B2 (en) * | 1989-12-18 | 1993-05-06 | Alcon Laboratories, Inc. | Compositions of antiallergics and antihistamines and methods for their use |
| US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| DE69333850T3 (de) | 1992-05-06 | 2011-03-17 | Alcon Laboratories, Inc., Fort Worth | Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen |
| US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| JP3527256B2 (ja) | 1992-12-09 | 2004-05-17 | ロート製薬株式会社 | 抗アレルギー点眼剤 |
| US5668133A (en) | 1992-12-09 | 1997-09-16 | Alcon Laboratories, Inc. | Ophthalmic compositions comprising emedastine and methods for their use |
| US5370744B1 (en) * | 1993-08-27 | 1999-11-09 | Alcon Lab Inc | Process for cleaning and disinfecting contact lenses |
| US5603929A (en) | 1994-11-16 | 1997-02-18 | Alcon Laboratories, Inc. | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
| JP3297969B2 (ja) * | 1994-12-26 | 2002-07-02 | ライオン株式会社 | 点眼剤 |
| US5641805A (en) | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
| AU721273B2 (en) * | 1996-09-20 | 2000-06-29 | Bausch & Lomb Incorporated | Method and composition for rewetting contact lenses and relieving eye dryness |
| ZA9811445B (en) * | 1997-12-19 | 1999-08-16 | Alcon Lab Inc | Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions. |
| JP4545927B2 (ja) * | 1998-04-07 | 2010-09-15 | アルコン ラボラトリーズ， インコーポレイテッド | キサンタンガムを含有するゲル化眼科用組成物 |
| JP3407654B2 (ja) * | 1998-04-14 | 2003-05-19 | ライオン株式会社 | 眼科用組成物 |
| US6146622A (en) * | 1998-10-27 | 2000-11-14 | Alcon Laboratories, Inc. | Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions |
-
2001
- 2001-01-24 PT PT01906672T patent/PT1250133E/pt unknown
- 2001-01-24 AU AU34556/01A patent/AU776789B2/en not_active Ceased
- 2001-01-24 JP JP2001554671A patent/JP2003520813A/ja not_active Ceased
- 2001-01-24 EP EP01906672A patent/EP1250133B1/en not_active Expired - Lifetime
- 2001-01-24 ES ES01906672T patent/ES2236180T3/es not_active Expired - Lifetime
- 2001-01-24 CA CA002395866A patent/CA2395866C/en not_active Expired - Fee Related
- 2001-01-24 DE DE60109742T patent/DE60109742T2/de not_active Expired - Lifetime
- 2001-01-24 WO PCT/US2001/002418 patent/WO2001054687A1/en not_active Ceased
- 2001-01-24 AT AT01906672T patent/ATE291913T1/de active
- 2001-01-24 US US09/768,444 patent/US6375973B2/en not_active Expired - Lifetime
-
2011
- 2011-03-31 JP JP2011080095A patent/JP2011132259A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU3455601A (en) | 2001-08-07 |
| DE60109742T2 (de) | 2005-08-18 |
| CA2395866A1 (en) | 2001-08-02 |
| AU776789B2 (en) | 2004-09-23 |
| EP1250133B1 (en) | 2005-03-30 |
| DE60109742D1 (de) | 2005-05-04 |
| WO2001054687A1 (en) | 2001-08-02 |
| ES2236180T3 (es) | 2005-07-16 |
| PT1250133E (pt) | 2005-05-31 |
| ATE291913T1 (de) | 2005-04-15 |
| US20010056093A1 (en) | 2001-12-27 |
| EP1250133A1 (en) | 2002-10-23 |
| US6375973B2 (en) | 2002-04-23 |
| JP2003520813A (ja) | 2003-07-08 |
| JP2011132259A (ja) | 2011-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2395866C (en) | Ophthalmic anti-allergy compositions suitable for use with contact lenses | |
| EP0739197B1 (en) | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds | |
| US7402609B2 (en) | Olopatadine formulations for topical administration | |
| AU2005311738B2 (en) | Topical nepafenac formulations | |
| AU709580B2 (en) | Preservative systems for pharmaceutical compositions containing cyclodextrins | |
| WO1996030022A1 (en) | Topical ophthalmic formulations comprising an acidic drug, vitamin e tpgs, benzalkonium chloride and caffeine | |
| AU2002310461A1 (en) | Olopatadine formulations for topical administation | |
| JP2003520813A5 (enExample) | ||
| EP1283043B1 (en) | Ophthalmic solution | |
| CN101087607A (zh) | 眼用组合物及使用其的方法 | |
| CA2758858C (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
| JP2005075735A (ja) | オキシメタゾリン含有組成物 | |
| HK1012556B (en) | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds | |
| HK1059573B (en) | Olopatadine formulations for topical administration | |
| JPWO2000028998A1 (ja) | 眼用液剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190124 |